The Magazine for Sleep Professionals
Sunday, January 11, 2026
Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore. Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) […]
Attendees traveled from near and far to join us in person and online for the 2025 Wake Up Narcolepsy National Summit in Raleigh-Durham, N.C. Hosted in a different city each year, the summit provides a place where industry professionals, clinicians, individuals with narcolepsy, and family members can come together and […]
My family loves to play games. One of the first things my husband and I bonded over was board games, and we passed that love of games to our children. As a family, we enjoy playing board games like Settlers of Catan and Carcassonne and card games like Dominion and […]
Noctrix Health, Inc., the developer of the Nidra® Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS), announced a significant expansion of private financing to accelerate its U.S. commercial launch. The company also announced several key leadership appointments to strengthen its commercial and scientific teams. Financing Update Noctrix Health […]
Millions of people worldwide who suffer with chronic insomnia are all too familiar with its profound impact on cognitive function, mood, and overall health and well-being. Many of these patients have success with first-line treatments like cognitive behavioral therapy (CBT) and pharmacological interventions, but relief remains elusive for many with […]
Specific types of gut bacteria may increase or decrease the risk for insomnia, while insomnia itself may in turn alter the abundance of certain gut bacteria, a new study showed. However, outside experts challenged the investigators’ assertion that the link is causal. Investigators identified 14 groups of bacteria associated with increased […]
EnsoData has announced a collaboration with Takeda to jointly develop and validate AI-based polysomnography (PSG) algorithms to support more accurate and scalable diagnosis of narcolepsy type 1 (NT1). Upon successful validation and regulatory clearance, EnsoData will pursue the clinical availability and release of AI algorithms to enable future access, use, […]
Nonin Medical has announced the launch of the Nonin Health® platform. The purpose-built cloud-based data ecosystem and software platform is designed for durable and home medical equipment (DME/HME) providers, sleep dentists, and sleep labs. With more than 1.5 million Americans currently requiring supplemental oxygen and millions more managing sleep-related breathing disorders, health care […]
ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy®, today announced significant progress on strategic programs. The key feature is the successful FDA registration of the company’s HWO2 buccal mucosal wellness oximeter. The ProSomnus HWO2 Device enables patients to monitor their nightly health and wellness during […]
Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system (hypoglossal nerve stimulation) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Genio is […]
